The Placebo Effect in Clinical Trials for Alcohol Dependence: An Exploratory Analysis of 51 Naltrexone and Acamprosate Studies

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 12, 2013, Pages 2128-2137

  Litten, Raye Z ^a   Castle, I Jen P ^b   Falk, Daniel ^a   Ryan, Megan ^a   Fertig, Joanne ^a   Chen, Chiung M ^b   Yi, Hsiao Ye ^b  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b CSR INCORPORATED   (United States)

Author keywords

Acamprosate; Alcohol Dependence; Meta Analysis; Naltrexone; Placebo Effect

Indexed keywords

ACAMPROSATE; ALCOHOL; NALTREXONE;

ALCOHOL ABSTINENCE; ALCOHOL BLOOD LEVEL; ALCOHOLISM; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG USE; FOLLOW UP; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ACAMPROSATE; ALCOHOL DEPENDENCE; META-ANALYSIS; NALTREXONE; PLACEBO EFFECT;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE; TREATMENT OUTCOME;

EID: 84897046357     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12197     Document Type: Article

References (99)

1. Ahmadi J, Ahmadi N (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. German J Psychiatry 5:85-89.
2. American Psychiatric Association (1980) Diagnotic and Statistical Manual of Mental Disorders. 3rd ed. American Psychiatric Association, Washington, DC.
3. American Psychiatric Association (1987) Diagnotic and Statistical Manual of Mental Disorders. 3rd ed. revised. American Psychiatric Association, Washington, DC.
4. American Psychiatric Association (1994) Diagnotic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington DC.
5. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R (2005) Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 25:349-357.
6. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758-1764.
7. Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, Randall PK (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 168:709-717.
8. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
9. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63:1426-1434.
10. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142-1149.
11. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103:2035-2044.
12. Baltieri DA, De Andrade AG (2004) Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 65:136-139.
13. Barrias J, Chabac S, Ferreira L, Fonte A, Potgieter AS, Teixeira de Sousa E (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 18:149-160.
14. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573-579.
15. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA (2009) Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42-49.
16. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000a) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35:587-593.
17. Chick J, Howlett H, Morgan MY, Ritson B (2000b) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35:176-187.
18. Del Re AC, Maisel N, Blodgett J, Finney J (2013) The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis. Alcohol Clin Exp Res 37:1064-1068.
19. Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ (2001) The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol 21:561-568.
20. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003) The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115-127.
21. Feinn R, Kranzler HR (2005) Does effect size in naltrexone trials for alcohol dependence differ for single-site vs multi-center studies? Alcohol Clin Exp Res 29:983-988.
22. Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tioririne NA, Johnson BA, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, Tompkins DA, Stout R (2012) A double-blind, placebo-controlled trial assessing the effiacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 36:1421-1430.
23. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375:686-695.
24. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22:592-598.
25. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Results of a randomised, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. Eur Addict Res 3:129-137.
26. de Goes e Castro LA (2004) Randomized, double-blind clinical trial with naltrexone and brief therapy for the in-patient treatment of alcohol dependence [Ensaio Clinico duplo-cego randomizado e placebo-controlado com naltrexona associado a intervencao breve no treatmento ambulatorial da dependencia alcohol]. Unpublished dissertation. Federal University of Sao Paulo.
27. Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 36:413-418.
28. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381-1387.
29. Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E (2004) A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 28:1356-1361.
30. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ (2008) Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336:999-1003.
31. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dube S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36:504-509.
32. Khan A, Detke M, Khan SR, Mallinckrodt C (2003) Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 191:211-218.
33. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychopharmacol 72:464-472.
34. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92-99.
35. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
36. Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JB, Cook IA, Leon AC, Alpert J (2010) Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol 30:193-197.
37. Kranzler HR, Gage A (2008) Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 17:70-76.
38. Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22:1074-1079.
39. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22:493-503.
40. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335-1341.
41. Kranzler HR, Wesson DR, Billot L (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28:1051-1059.
42. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734-1739.
43. Ladewig D, Knecht T, Leher P, Fendl A (1993) Acamprosate-a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50:182-188.
44. Lane P (2008) Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 7:93-106.
45. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176:530-534.
46. Lee A, Tan S, Lim D, Winslow RM, Wong KE, Allen J, Hall W, Parker G (2001) Naltrexone in the treatment of male alcoholics-an effectiveness study in Singapore. Drug Alcohol Rev 20:193-199.
47. Lee S, Malhotra B, Creanga D, Carlsson M, Glue P (2009) A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 9:55.
48. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1:1014-1016.
49. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F, et al. (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25:613-622.
50. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernandez R, Phillips AG, Stoessl AJ (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67:857-865.
51. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NAD, Kampman K, Stout R (2012) A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 36:406-416.
52. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275-293.
53. Mallinckrodt CH, Tamura RN, Tanaka Y (2011) Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res 45:1202-1207.
54. Mallinckrodt CH, Zhang L, Prucka WR, Millen BA (2010) Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 43:53-72.
55. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28:51-63.
56. Mason BJ, Lehert P (2012) Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 36:497-508.
57. Merlo-Pich E, Alexander RC, Fava M, Gomeni R (2010) A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 88:634-642.
58. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634-1647.
59. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101:1451-1462.
60. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96:1565-1573.
61. Nunes EV, Levin FR (2004) Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 291:1887-1896.
62. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881-887.
63. O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D (2008) Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 32:1271-1283.
64. O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R (2007) Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res 31:625-634.
65. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5:324-332.
66. Oslin DW (2005) Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry 13:491-500.
67. Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, Ten Have T, Wortman S, Dundon W, Dackis C, Volpicelli JR, O'Brien CP (2008) A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 32:1299-1308.
68. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30:239-247.
69. Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34-40.
70. Pelc I, Le Bon O, Verbanck P, Lehert P, Opsomer L (1992) Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicenter study, in Novel Pharmacological Interventions for Alcoholism (Naranjo C, Sellers E eds), pp 348-352. Springer, New York.
71. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73-77.
72. Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 172:291-297.
73. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57:1128-1137.
74. Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, O'Brien CP (2008) Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat 34:378-390.
75. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP (2010) A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 167:668-675.
76. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537-1546.
77. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev (9):CD004332.
78. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (12):CD001867.
79. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673-680.
80. Selzer ML (1971) The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127:1653-1658.
81. Siddiqui O (2011) MMRM versus MI in dealing with missing data-a comparison based on 25 NDA data sets. J Biopharm Stat 21:423-436.
82. Siddiqui O, Hung HMJ, O'Neill R (2009) MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 19:227-246.
83. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctot KL (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71:270-279.
84. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91:199-209.
85. Srisurapanont M, Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8:267-280.
86. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544-552.
87. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-Analysis in Medical Research. John Wiley & Sons, Ltd, West Sussex, UK.
88. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35:202-209.
89. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573.
90. Undurraga J, Baldessarini RJ (2012) Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37:851-864.
91. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880.
92. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-742.
93. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840-1847.
94. Walsh BT, Sysko R (2005) Placebo control groups in trials of major depressive disorder among older patients. J Clin Psychopharmacol 25:S29-S33.
95. Weiss RD, O'Malley SS, Hosking JD, Locastro JS, Swift R (2008) Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 69:878-884.
96. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438-1442.
97. Wilson DB (2010) Meta-analysis macros for SAS, SPSS, and Stata. Available at: http://mason.gmu.edu/~dwilsonb/ma.html. Accessed November 9, 2011.
98. Wölwer W, Frommann N, Janner M, Franke PE, Scherbaum N, Lieb B, Falkai P, Wobrock T, Kuhlmann T, Radermacher M, Maier W, Schutz C, Ohmann C, Burtscheidt W, Gaebel W (2011) The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend 118:417-422.
99. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland.